Points in Summary:
1. Why we need to redraw the battle plan—one that focuses on turning the treatment system into a research and learning system that can teach oncologists the best use of the weapons they already have
2. drug and biotechnology industries are lavishing increased attention on cancer (861 drugs and vaccines in clinical trials, according to a recent announcement) most of the newly approved agents that squeeze through the pipeline extend the lives of patients for only a few weeks or months, often at great expense. The outcomes are never gathered. The data is never analyzed. the findings are never disseminated
3. As these patients’ cancers advance, their physicians try regimens they read about in journals or hear about from colleagues. The outcomes are never gathered. The data is never analyzed. And the findings are never disseminated.
4. an estimated 70 percent of all cancer drugs are used off-label. In other words, most prescribed chemotherapy regimens have not been approved by the Food and Drug Administration for that particular use. Much of the off-label use is supported by the slimmest of evidence, often just a single trial in the medical literature of limited size and duration.
5. Pediatric oncologists on the other hand, steadily refine the treatment regimens base don their success in using shared data and results in trials to the point where survival rates today are over 80 percent, up from 20 percent in the 1960s. Adult tumors can take decades to develop and are resistant to treatment. Pediatric cancers, in contrast, usually “arise from embryonic development and develop into cancers that are much more susceptible to chemotherapy and radiation
6. Focus on collecting extensive information about the 1.3 million Americans who are diagnosed and treated for cancer every year. Let nation’s physicians move toward adopting electronic medical records. This will enable oncologists to record their patients’ demographic and genetic information their diagnoses, their treatments, and, eventually, their outcomes. This information could then be analyzed retrospectively to see what works and translated into guidelines for better care if the data is in the database, you can answer that question in a few hours, or maybe even a few minutes .
7. The National Cancer Institute recently took a major step in building an information superhighway to serve a cancer learning network. The ambitious goal behind CaBIG, the Cancer Biomedical Infomatics Grid, is nothing less than turning the billions the nation spends each year on cancer care into that “learning system
An article from American Psychiatric Association noting the similarities between the victims of well-acknowledged trauma and the experience of the cancer patient.
An article published in Dana Farber's magazine Paths of Progress about me and two of my close friends who are also childhood cancer survivors of ALL. One of them is srisko.
BCAN has a downloadable (pdf) phamphlet that can be printed off. I wish I had this before I went for my cystoscopy.
A LIFE SAVING MESSAGE
CAUSE FOR CANCER
Scientists at Dulwich Health Society, USA, studied over 25,000 people with ill health and concluded that the following groups are Geopathically Stressed (GS):
•100% of people who get SECONDARY CANCER.
•95% of people who get CANCER were sleeping &/or working in a Geopathic stressed place before or at the time the cancer was diagnosed .
The term ‘Geopathic Stress’ is used to describe negative energies, also known as ‘harmful earth rays’, which emanate from the earth and cause discomfort and ill health to those living above.
Underground water-flows beneath a property or structure. When a structure is built above underground water, the natural magnetic flow of the water energy is restricted, and disruptive vibrations are set up in the building. Thus, if we sleep above these flows, over a period of time, the body's resistance can be affected, leading to stress and weakening of our IMMUNE System.
Geopathic Stress is the only common factor in most serious and long term illnesses and psychological conditions.
•Thousands of medical doctors and therapists now confirm that any Geopathic Stress (GS) must be cleared before any treatment can be 100% successful.
CANCER is the most notorious of these, and tumours are known to develop almost always at exactly the spot where two or more GS lines cross a person’s body as they lie asleep in their bed.
“ Cancer is a disease of location triggered off by geopathic stress. We all produce cancerous cells on a regular basis, but they are continuously destroyed by our body's immune system. Geopathic stress does not cause cancer, but weakens our immune system. Dr Ernst Hartmann, MD”
We are a wellness consutancy company , located in Chennai , India, and we have developed instruments to precisely pinpoint the Geopathic Stress lines passing through a house or any place of dwelling and clear the same permanently, with very affordable gadgets.
Should you be interested to work with us, we are more than ready for the co operation.
For more information on Geopathic Stress please visit our blog: www.geopathicdanger.blogspot.com. e mail: firstname.lastname@example.org
Let us WORK together to banish CANCER.
With best wishes
K.Kannan /CEO/PORTOWORLD/ Chennai, India. Mob: 09381044542 www.geopathicdanger.blogspot.com. Email: email@example.com
HUNTINGTON BEACH, CA., August 11, 2008 - Today’s online edition of the Journal of Internal Medicine reports discovery of the first practical laboratory test to guide the use of new-generation drugs that kill cancer cells by cutting off their blood supply. The new test, called the Microvessel Vascular (MVV) assay, was developed by Larry Weisenthal, MD, PhD., a medical oncologist who operates a cancer testing laboratory in Huntington Beach, California. The test works by measuring drug effects upon endothelial cells which make up blood vessels. Its use could prolong lives, save money, and spare patients exposure to harmful side-effects of ineffective chemotherapy treatments. The MVV test also could streamline development of new anti-cancer cancer drugs and identify effective and sometimes unexpected new drug combinations, such as one reported in the article. Used today principally by cancer physicians, to choose effective therapies on a patient-by-patient basis, the MVV assay also has potential for use as an early-warning screen for a variety of illnesses ranging from heart disease, cancer, diabetes, autoimmune disorders, and many others. Patents have been filed.
Dr. Weisenthal invented his new test after making the discovery that endothelial cells are present in cancer biopsy specimens even after the specimens are reduced to clusters of living cancer cells in order to make them suitable for testing in the laboratory. Endothelial cells form capillaries which carry oxygen and nutrients to cancer cells. Dr. Weisenthal noted that the effects of various drugs upon endothelial cells can be measured separately from the effects of those same drugs upon cancer cells within the same biopsy specimen. Dr. Weisenthal describes this as “anti-vascular effect versus anti-tumor effect.” Using this discriminatory property of his new test, Dr. Weisenthal has published several, original and often unexpected observations about the ways in which various drugs work.
Dr. Weisenthal further describes a logical extension of the MVV test, in which the ability to identify and characterize endothelial cells in mixed-cell populations could lead to early diagnosis and thereby more successful treatment of a broad spectrum of illnesses for which elevated numbers of circulating endothelial cells can be a feature. Potentially included are cancer, heart disease, diabetes, macular degeneration and others. Dr. Weisenthal envisions an accurate and inexpensive test, performed annually and based upon a simple blood draw, which would warn of the possible presence of a medical condition for which additional tests were warranted. The result would be earlier diagnosis of disease and also avoidance of much of the expensive and often unnecessary medical testing which occurs today.
The most immediate application of the MVV assay focuses upon cancer and specifically upon a much-heralded new class of agents called angiogenesis-inhibiting drugs, which work by attacking tumor vasculature and thereby starving cancer cells. A recent NIH listing contained over 800 active clinical trials involving angiogenesis-inhibiting agents. One such drug, called Avastin® (Genentech, South San Francisco, CA) had sales topping $2.2 billion in the U.S. alone in 2007. Many more angiogenesis-inhibiting drugs are in development.
One problem with these drugs, in addition to their high cost, is determining in advance who will benefit from them. The other problem is learning how to make the drugs more effective by using them in combination. The new MVV test could help on both fronts.
Dr Weisenthal expresses his belief that cancer can become a chronic and controllable illness through the use of combinations of anti-angiogenesis drugs. He says, “The long-awaited magic-bullet cure for cancer hasn’t materialized. Now we’re thinking more in terms of long-term control such as is the case with high blood pressure or diabetes. The way to make that happen sooner is to use our current ammunition more affectively.”
Dr. Weisenthal’s observations are reinforced by early studies of angiogenesis-inhibiting drugs in animal tumor models. In these studies, single agents produced only sporadic and temporary benefits. However, the effectiveness of these drugs increased substantially when they were administered in combination with other angiogenesis-inhibiting drugs. According to Dr. Weisenthal, the MVV test is the first practical tool that allows for design and testing of new anti-angiogenic drug combinations in human cancer.
Using his new MVV test, Dr. Weisenthal says that he often finds strong synergies among new combinations of different types of angiogenesis-inhibiting drugs, including drugs which were not previously known to have anti-angiogenic properties. One observation, which he reports in the Journal of Internal Medicine article, is that dimethylsulfoxide and ethanol are two compounds which often enhance the activity of anti-angiogenesis drugs in the laboratory. According to Dr. Weisenthal, therapeutic levels of ethanol in the bloodstream theoretically could be achieved simply by drinking wine or another alcoholic beverages in prescribed doses concurrent with receiving angiogenesis-inhibiting drugs. The concept might please some patients and alarm others but Dr. Weisenthal finds support in actual case studies reported in the medical literature. However, he warns that further clinical studies are required.
The MVV test is applicable to cancer patients whose bodies harbor cancer cells which are obtainable though biopsy. Currently, the test is available only through Dr. Weisenthal’s laboratory, the Weisenthal Cancer Group. Dr. Weisenthal says that he provides his testing services more like a medical practice and less like a typical reference laboratory. Although he regularly performs testing for cancer patients in the U.S. and also from several foreign countries, he intends to to stick to medicine and leave marketing of the MVV test to others. Dr. Weisenthal says that he would like to see the test become available to patients worldwide through service agreements with larger laboratory companies or with a biotechnology company which might develop a testing kit for sale to hospitals and laboratories. He also would like to license the test to pharmaceutical companies for use in new drug development.
About Weisenthal Cancer Group: Weisenthal Cancer Group is a privately-held commercial cancer testing laboratory and research facility headquartered in Huntington Beach, California. The company was founded in 1992 by Larry Weisenthal, MD, PhD, a medical oncologist and Associate Clinical Professor of Medicine at the University of California Irvine. Dr. Weisenthal trained at the NCI and has served in a variety of advisory and review capacities. Dr. Weisenthal is widely published and has been a keynote speaker at numerous meetings and symposia presented by oncology societies in Europe and Asia. In 1987, Dr. Weisenthal was founder of Oncotech, an Irvine, California oncology-focused laboratory, acquired this year by Exiqon. Weisenthal Cancer Group provides functional tumor cell profiling studies and medical consultation to physicians and patients worldwide in connection with chemotherapy treatment.
The laboratory also provides contract and collaborative research services to biotech and pharmaceutical companies and to cancer researchers.
Colon and breast cancer patients who take Xeloda know the side effect Hand-Foot Syndrome (HFS) or Palmar-Plantar Erythrodysesthesia (PPE). A study at a university in Turkey looked at the use of henna in treating PPE. This webpage tells you how to use it. Reference to the Turkish study is given.